Q2 2025 Lifecore Biomedical Inc Earnings Call Transcript
Key Points
- Lifecore Biomedical Inc (LFCR) reported an 8% increase in quarterly revenues, reaching $32.6 million, driven by higher sales volumes from its largest customer.
- The company successfully completed a $24.3 million PIPE financing, significantly improving its liquidity position.
- Gross profit increased by $1.1 million compared to the same period last year, primarily due to price increases and a favorable sales mix.
- Lifecore signed multiple new projects, including a notable agreement with Nirsum Laboratories for CDMO services.
- The company installed a high-speed, multi-purpose five-head isolator filler, doubling its available capacity and enhancing its revenue-generating potential.
- Lifecore Biomedical Inc (LFCR) reported a net loss of $6.6 million for the quarter, compared to a net income of $14.2 million in the same period last year.
- Selling, general, and administrative expenses increased to $11.1 million, primarily due to higher non-cash stock-based compensation expenses.
- The company experienced a $0.5 million decrease in HA manufacturing gross profit due to manufacturing variances.
- Legal and audit costs increased, impacting the overall financial performance.
- Despite revenue growth, the company maintained its top-line revenue guidance without any upward revision.
Good afternoon, and thank you for joining Lifecore's financial 2025 second-quarter earnings call. (Operator Instructions)
Now, I would like to turn the call over to Stephanie Diaz, Manager of Investor Relations for Lifecore. Please go ahead.
Good afternoon, and thank you for joining us today to discuss Lifecore Biomedical's second-quarter fiscal 2025 earnings results. Hosting the call today from Lifecore are Paul Josephs, President and Chief Executive Officer; and Ryan Lake, Chief Financial Officer.
Before we begin today, we'd like to remind everyone that certain statements made in the course of this conference call contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, January 2, 2025, and the company's actual results could differ materially from those projected in such forward-looking statements.
For a more thorough discussion of the risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
